Magnetic Resonance Versus Radionuclide Pharmacological Stress Perfusion Imaging for Flow-limiting Stenoses of Varying Severity
Overview
Authors
Affiliations
Background: Although magnetic resonance first-pass imaging (MRFP) has potential advantages in pharmacological stress perfusion imaging, direct comparisons of current MRFP and established radionuclide techniques are not available.
Methods And Results: Graded regional differences in coronary flow were produced during global coronary vasodilation in chronically instrumented dogs by partially occluding the left circumflex artery. Regional differences in full-thickness flow quantified using microspheres were compared with regional differences obtained with MRFP and radionuclide SPECT imaging (99mTc-sestamibi and 201Tl). Relative regional flows (RRFs) derived from the initial areas under MRFP signal intensity-time curves were linearly related to reference microsphere RRFs over the full range of vasodilation (y=0.93x+4.3; r2=0.77). Relationships between 99mTc-sestamibi and 201Tl RRFs and microsphere RRFs were curvilinear, plateauing as flows increased. The high spatial resolution of the MRI enabled transmural flow to be evaluated in 3 to 5 layers across the myocardial wall. Reductions in subendocardial flow were visually apparent in MRFP images for > or =50% reductions in full-thickness flow. Endocardial-to-epicardial gradients in MRFP flow increased progressively with stenosis severity, whereas transmural flow patterns in remote normally perfused myocardium remained normal. Flow reductions of > or =50% not identified by radionuclide imaging were apparent in MRFP full-thickness and transmural analyses.
Conclusions: High-resolution MRFP can identify regional reductions in full-thickness myocardial blood flow during global coronary vasodilation over a wider range than current SPECT imaging. Transmural flow gradients can also be identified; their magnitude increases progressively as flow limitations become more severe and endocardial flow is compromised increasingly.
New Targets in Heart Failure Drug Therapy.
Correale M, Tricarico L, Fortunato M, Mazzeo P, Nodari S, Di Biase M Front Cardiovasc Med. 2021; 8:665797.
PMID: 34026873 PMC: 8131549. DOI: 10.3389/fcvm.2021.665797.
How Do PET Myocardial Blood Flow Reserve and FFR Differ?.
Johnson N, Gould K Curr Cardiol Rep. 2020; 22(4):20.
PMID: 32052198 PMC: 7015869. DOI: 10.1007/s11886-020-1274-x.
Hsu L, Jacobs M, Benovoy M, Ta A, Conn H, Winkler S JACC Cardiovasc Imaging. 2018; 11(5):697-707.
PMID: 29454767 PMC: 8760891. DOI: 10.1016/j.jcmg.2018.01.005.
Chatterjee N, Benefield B, Harris K, Fluckiger J, Carroll T, Lee D Magn Reson Med. 2016; 77(6):2347-2355.
PMID: 27605488 PMC: 5407936. DOI: 10.1002/mrm.26326.
Introduction to Cardiovascular Magnetic Resonance: Technical Principles and Clinical Applications.
Tseng W, Su M, Tseng Y Acta Cardiol Sin. 2016; 32(2):129-44.
PMID: 27122944 PMC: 4816912. DOI: 10.6515/acs20150616a.